2024–2025 Drug Updates in Solid Tumors
Journal of the Advanced Practitioner in Oncology · 27.02.2026 · 17 (2)
DOI: 10.6004/jadpro.2026.17.2.6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 27.02.2026. Verfasst von Kevin Y. Chen und 4 weiteren Autor:innen.
Abstract (Originalsprache)
At JADPRO Live 2025, Kevin Y. Chen, PharmD, MS, BCOP, CPP, reviewed therapeutic advances in solid tumors with an emphasis on newly approved targeted therapies and antibody–drug conjugates (ADCs). The session underscored the expanding role of biomarker-driven treatment selection and comprehensive molecular profiling. Dr. Chen also emphasized the role of oncology advanced practitioners in monitoring patients and managing toxicities of these agents in order to optimize outcomes.
Zitieren
APA
Chen, K. Y., PharmD, MS, BCOP, & CPP (2026). 2024–2025 Drug Updates in Solid Tumors. Journal of the Advanced Practitioner in Oncology, 17(2). https://doi.org/10.6004/jadpro.2026.17.2.6
Vancouver
Chen KY, PharmD, MS, BCOP, CPP. 2024–2025 Drug Updates in Solid Tumors. Journal of the Advanced Practitioner in Oncology. 2026;17(2). doi:10.6004/jadpro.2026.17.2.6
BibTeX
@article{Chen2026,
author = {Chen, Kevin Y. and PharmD and MS and BCOP and CPP},
title = {2024–2025 Drug Updates in Solid Tumors},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {2},
doi = {10.6004/jadpro.2026.17.2.6}
}
EUVIMED